Jose U Scher

List of Publications by Year
in descending order

94 papers	8,820 citations	66343 42 h-index	54911 84 g-index
102 all docs	102 docs citations	102 times ranked	12710 citing authors

#	Article	IF	Citations
1	Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. ELife, 2013, 2, e01202.	6.0	1,507
2	Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease. Arthritis and Rheumatology, 2015, 67, 128-139.	5.6	602
3	Periodontal disease and the oral microbiota in newâ€onset rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3083-3094.	6.7	399
4	The microbiome and rheumatoid arthritis. Nature Reviews Rheumatology, 2011, 7, 569-578.	8.0	381
5	Covid-19 in Immune-Mediated Inflammatory Diseases â€" Case Series from New York. New England Journal of Medicine, 2020, 383, 85-88.	27.0	377
6	The role of the gut microbiome in systemic inflammatory disease. BMJ: British Medical Journal, 2018, 360, j5145.	2.3	367
7	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis and Rheumatology, 2019, 71, 5-32.	5.6	312
8	15d-PGJ2: The anti-inflammatory prostaglandin?. Clinical Immunology, 2005, 114, 100-109.	3.2	298
9	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care and Research, 2019, 71, 2-29.	3.4	264
10	Short- and long-term effects of oral vancomycin on the human intestinal microbiota. Journal of Antimicrobial Chemotherapy, 2017, 72, 128-136.	3.0	233
11	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nature Reviews Rheumatology, 2019, 15, 153-166.	8.0	208
12	The Anti-Inflammatory Effects of Prostaglandins. Journal of Investigative Medicine, 2009, 57, 703-708.	1.6	206
13	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases, 2021, 80, 1339-1344.	0.9	202
14	Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Current Opinion in Rheumatology, 2014, 26, 101-107.	4.3	187
15	Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis and Rheumatology, 2016, 68, 35-45.	5.6	187
16	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16814-16819.	7.1	185
17	The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome, 2016, 4, 60.	11.1	158
18	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet, The, 2020, 395, 427-440.	13.7	122

#	Article	IF	Citations
19	Distinct Polysaccharide Utilization Profiles of Human Intestinal Prevotella copri Isolates. Cell Host and Microbe, 2019, 26, 680-690.e5.	11.0	115
20	Psoriatic arthritis. Nature Reviews Disease Primers, 2021, 7, 59.	30.5	113
21	The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nature Reviews Rheumatology, 2016, 12, 446-455.	8.0	112
22	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following <scp>SARS</scp>â€“<scp>CoV</scp>â€2 Vaccination. Arthritis and Rheumatology, 2022, 74, 284-294.	5.6	103
23	Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. Scientific Reports, 2017, 7, 15613.	3.3	100
24	COVIDâ€19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Diseaseâ€Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis and Rheumatology, 2020, 72, 1981-1989.	5.6	92
25	Gut Microbiota Perturbations in Reactive Arthritis and Postinfectious Spondyloarthritis. Arthritis and Rheumatology, 2018, 70, 242-254.	5.6	88
26	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2â€”Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. Journal of the American Academy of Dermatology, 2021, 84, 1254-1268.	1.2	88
27	Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis. Current Opinion in Rheumatology, 2014, 26, 424-429.	4.3	81
28	Auto-deconvolution and molecular networking of gas chromatographyâ€“mass spectrometry data. Nature Biotechnology, 2021, 39, 169-173.	17.5	78
29	The Pretreatment Gut Microbiome Is Associated With LackÂof Response to Methotrexate in Newâ€Onset Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 931-942.	5.6	78
30	Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nature Reviews Rheumatology, 2020, 16, 282-292.	8.0	76
31	Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis. Microbiome, 2017, 5, 63.	11.1	73
32	Nitric oxide synthases and osteoarthritis. Current Rheumatology Reports, 2007, 9, 9-15.	4.7	71
33	Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host and Microbe, 2021, 29, 362-377.e11.	11.0	70
34	Inflammasome Signaling and Impaired Vascular Health in Psoriasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 787-798.	2.4	66
35	Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology, 2016, 55, keu469.	1.9	62
36	Helicobacter pylori Stimulates Gastric Epithelial Cell MMP-1 Secretion via CagA-dependent and -independent ERK Activation. Journal of Biological Chemistry, 2007, 282, 18722-18731.	3.4	57

#	Article	IF	Citations
37	Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1340-1351.	2.4	56
38	The microbiome in rheumatology: Where are we and where should we go?. Annals of the Rheumatic Diseases, 2020, 79, 727-733.	0.9	55
39	Interleukinâ€17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukinâ€25â€“Driven Intestinal Inflammation. Arthritis and Rheumatology, 2020, 72, 645-657.	5.6	51
40	Leveraging the United States Epicenter to Provide Insights on COVIDâ€19 in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1971-1980.	5.6	51
41	Psoriatic arthritis from a mechanistic perspective. Nature Reviews Rheumatology, 2022, 18, 311-325.	8.0	49
42	Matrix Metalloproteinase Secretion by Gastric Epithelial Cells Is Regulated by E Prostaglandins and MAPKs. Journal of Biological Chemistry, 2005, 280, 9973-9979.	3.4	48
43	Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease?. Arthritis Research and Therapy, 2013, 15, 122.	3.5	45
44	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Journal of the American Academy of Dermatology, 2020, 83, 1704-1716.	1.2	43
45	Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures. Blood, 2021, 138, 1456-1464.	1.4	39
46	MicrobiotaâEDependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis. Arthritis and Rheumatology, 2018, 70, 1971-1983.	5.6	37
47	Key opinion leaders â€" a critical perspective. Nature Reviews Rheumatology, 2021, 17, 119-124.	8.0	36
48	Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease. Annals of the Rheumatic Diseases, 2020, 79, 400-407.	0.9	35
49	KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. Journal of Clinical Investigation, 2020, 130, 3151-3157.	8.2	34
50	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. Journal of Rheumatology, 2017, 44, 693-694.	2.0	33
51	Augmented Th17 Differentiation Leads to Cutaneous and Synovioâ€Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 855-867.	5.6	29
52	Does biologic therapy impact the development of PsA among patients with psoriasis?. Annals of the Rheumatic Diseases, 2022, 81, 80-86.	0.9	29
53	Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatology, The, 2022, 4, e384-e387.	3.9	27
54	Human microbiome, infections, and rheumatic disease. Clinical Rheumatology, 2017, 36, 2645-2653.	2.2	26

#	Article	IF	Citations
55	CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. Journal of the American Academy of Dermatology, 2021, 84, 913-920.	1.2	26
56	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nature Reviews Rheumatology, 2021, 17, 238-243.	8.0	23
57	Association of medication beliefs and self-efficacy with adherence in urban Hispanic and Africanâ€“American rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2014, 73, 317-318.	0.9	22
58	Biomarkers in Psoriatic Arthritis: Recent Progress. Current Rheumatology Reports, 2014, 16, 453.	4.7	21
59	Strategies to Improve Outcomes in Psoriatic Arthritis. Current Rheumatology Reports, 2019, 21, 72.	4.7	19
60	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. Journal of Investigative Dermatology, 2021, 141, 2112-2122.e3.	0.7	19
61	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. Lancet Rheumatology, The, 2021, 3, e585-e594.	3.9	18
62	The Microbiome in Psoriasis and Psoriatic Arthritis: Joints. Journal of Rheumatology, 2018, 94, 32-35.	2.0	18
63	Spondyloarthritis and the Microbiome: New Insights From an Ancient Hypothesis. Current Rheumatology Reports, 2015, 17, 10.	4.7	16
64	B-cell therapies for rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases, 2012, 70, 200-3.	0.7	16
65	Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. Journal of Rheumatology, 2020, 47, 1496-1505.	2.0	14
66	A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation.. Journal of Investigative Dermatology, 2021, , .	0.7	13
67	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 31-58.	0.7	12
68	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Current Rheumatology Reports, 2020, 22, 78.	4.7	10
69	Microbial-derived antigens and metabolites in spondyloarthritis. Seminars in Immunopathology, 2021, 43, 163-172.	6.1	10
70	Not your average joint: Towards precision medicine in psoriatic arthritis. Clinical Immunology, 2020, 217, 108470.	3.2	9
71	A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. Rheumatology, 2021, 60, 2307-2316.	1.9	9
72	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatology, The, 2022, 4, e582-e585.	3.9	9

#	Article	IF	Citations
73	Intestinal Dysbiosis and Potential Consequences of Microbiome-altering Antibiotic Use in the Pathogenesis of Human Rheumatic Disease. Journal of Rheumatology, 2015, 42, 355-357.	2.0	7
74	Potential risk factors for reactive arthritis and persistence of symptoms at 2Âyears: a case-control study with longitudinal follow-up. Clinical Rheumatology, 2018, 37, 415-422.	2.2	7
75	Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination. Rheumatology, 2021, 60, e225-e226.	1.9	7
76	OP0108â€…DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÃVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
77	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201671.	2.0	6
78	Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. Arthritis and Rheumatology, 2021, 73, 1574-1578.	5.6	6
79	Prevalence, Predictors, and Disease Activity of Sacroiliitis Among Patients with Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2021, 27, 809-815.	1.9	5
80	The microbiome in celiac disease: Beyond diet-genetic interactions. Cleveland Clinic Journal of Medicine, 2016, 83, 228-230.	1.3	5
81	The 2018 landscape of RA, PsA, and SpA pathogenesis. Current Opinion in Rheumatology, 2018, 30, 57-58.	4.3	3
82	1206â€…Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus. , 2021, , .		2
83	COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study. JAAD International, 2022, 8, 31-33.	2.2	2
84	Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis. Journal of Rheumatology, 2022, , jrheum.211321.	2.0	1
85	Neutrophils I. , 0, , 39-48.		0
86	Reply. Arthritis and Rheumatology, 2015, 67, 2280-2282.	5.6	0
87	Periodontal Infections and Rheumatoid Arthritis. , 2016, , 107-115.		0
88	07.04â€…Partial elimination of intestinal microbiota dampens t helper 17 cell differentiation and established collagen-induced arthritis in mice. , 2017, , .		0
89	Response to: â€˜Microbiome in SjÃ¶grenâ€™s syndrome: here we areâ€™ by van der Meulenet al. Annals of the Rheumatic Diseases, 2022, 81, e115-e115.	0.9	0
90	Another â€˜BEEâ€™? â€“ Brain-Eye-Ear (BEE) Disease Secondary to HbSC Disease Masquerading as Multiple Sclerosis. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105618.	1.6	0

#	Article	IF	Citations
91	Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. Current Opinion in Rheumatology, 2021, 33, 409-411.	4.3	0
92	The microbiome in rheumatic diseases. , 2015, , 145-151.		0
93	Microbiome and Microbiota in Rheumatic Disease. , 2019, , 11-19.		0
94	GRAPPA 2020 Research Award Recipients. Journal of Rheumatology, 2022, , jrheum.211335.	2.0	0